Abecma (idecabtagene vicleucel)
Bristol Myers Squibb / 2seventy bio · CAR-T Cell Therapy — BCMA-directed
What is Abecma? Abecma (idecabtagene vicleucel) is an anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma. It is a personalized, patient-specific product made from the patient's own T cells, which are engineered to target BCMA (B-cell maturation antigen) on myeloma cells.
About Abecma
| Brand Name | Abecma |
| Generic / INN | idecabtagene vicleucel |
| Drug Class | CAR-T Cell Therapy — BCMA-directed |
| Manufacturer | Bristol Myers Squibb / 2seventy bio |
| Administration | IV infusion (personalized, patient-specific autologous product) |
| FDA Approval | 2021 |
FDA-Approved Uses for Abecma
Indications are based on FDA approval. Your healthcare provider determines appropriate use based on your specific diagnosis, stage, biomarker status, and overall clinical picture.
- Relapsed or refractory multiple myeloma — adult patients who have received at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody
How Does Abecma Work?
Abecma is an autologous CAR-T product. The patient's T cells are collected via leukapheresis, genetically engineered ex vivo to express a chimeric antigen receptor (CAR) targeting BCMA, then expanded and infused back into the patient. Upon infusion, CAR-T cells recognize and kill BCMA-expressing multiple myeloma cells.
Dosage & Administration
Single infusion of 300–460 × 10⁶ CAR-positive T cells. Requires lymphodepleting chemotherapy (fludarabine + cyclophosphamide) before infusion. The entire process from leukapheresis to infusion takes several weeks. Must be administered at a REMS-certified healthcare facility.
Dosing is individualized by the prescribing clinician. Never adjust your dose without consulting your healthcare provider. This information is educational only and does not replace the official prescribing information.
Warnings, Precautions & Side Effects
General Warning
BOXED WARNING: Cytokine release syndrome (CRS) — can be severe or life-threatening. BOXED WARNING: Neurologic toxicity (ICANS) — can be severe or fatal. Hemophagocytic lymphohistiocytosis (HLH). Prolonged cytopenias. Secondary T-cell malignancies (reported). Hypersensitivity reactions. Infections. This product is available ONLY through the Abecma REMS Program.
- Cytokine release syndrome (CRS) — boxed warning
- Neurologic toxicity / ICANS — boxed warning
- Hemophagocytic lymphohistiocytosis (HLH)
- Secondary T-cell malignancies
- Prolonged severe cytopenias
Common Side Effects
- Cytokine release syndrome (CRS)
- Fatigue
- Cytopenias
- Neurologic toxicity
- Infection
- Hypotension
- Edema
This is not a complete list. Always report new or worsening symptoms to your healthcare provider promptly.
Storage & Handling
Cryopreserved in liquid nitrogen vapor phase (≤ −150°C). Specialized cold-chain transport and storage required at certified facilities. Do not thaw until immediately before infusion.
BiologicHealthPlus provides temperature-monitored cold-chain specialty delivery for medications requiring refrigeration. Never use a medication if its storage conditions have been compromised.
Insurance Coverage, Prior Authorization & Patient Assistance
🛡️ Commercial Insurance
Abecma is covered by most major commercial insurance plans when medically necessary and prior authorized. Coverage tier and cost-sharing vary by plan.
✅ Prior Authorization
Prior authorization is required by virtually all insurance plans for Abecma. BiologicHealthPlus handles the complete prior authorization process at no cost to patients or providers.
🏥 Medicare Coverage
Medicare Part B covers this IV medication when administered in a clinical setting. Medicaid coverage varies by state.
🆓 Patient Assistance
Manufacturer patient assistance programs may be available for eligible uninsured or underinsured patients. Contact BiologicHealthPlus for a confidential eligibility review.
Prior Authorization Patient Assistance Insurance & Savings Medication Costs
Frequently Asked Questions — Abecma
Abecma (idecabtagene vicleucel) is a CAR-T cell therapy approved for relapsed or refractory multiple myeloma. It is made from the patient's own T cells, engineered to target BCMA on myeloma cells. It is a one-time infusion, but the manufacturing process takes several weeks.
The patient's T cells are collected through leukapheresis, sent to a manufacturing facility where they are genetically modified to express a BCMA-targeting CAR, expanded, quality tested, and then shipped back for infusion. The process typically takes 4–6 weeks.
CRS is a potentially life-threatening immune reaction that can occur after CAR-T therapy, including Abecma. Symptoms range from mild (fever, fatigue) to severe (low blood pressure, organ dysfunction). It requires immediate management at a REMS-certified facility with access to tocilizumab.
Abecma is only available through the Abecma REMS Program and can only be administered at certified healthcare facilities. Patients must remain near the treatment center for at least 4 weeks post-infusion for monitoring.
Coverage for CAR-T therapies requires extensive prior authorization documentation. Commercial insurance and Medicare cover Abecma for eligible patients, though coverage varies. The cost of CAR-T therapy is extremely high — patient support and co-pay assistance programs exist. BiologicHealthPlus can assist with benefits verification and access coordination.
Related Medications & Conditions
Related Medications
Carvykti (ciltacabtagene autoleucel) · Darzalex (daratumumab) · Revlimid (lenalidomide) · Velcade (bortezomib)
Related Conditions
Relapsed/refractory multiple myeloma · Multiple myeloma · Plasma cell malignancies